Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 214 of 5804
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis study is a single-center, single-arm, open-label, investigator-initiated early exploratory clinical trial designed to evaluate the safety and efficacy of STR-P005 in subjects with relapsed/refractory autoimmune diseases. The study will employ the traditional "3+3" dose esca…
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation therapy targets Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThis study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo aims to slow advanced cervical cancer
Disease control Not yet recruitingAdvanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThe overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclero…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New lung cancer cocktail trial aims to shrink tumors
Disease control Not yet recruitingThis is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare blood cancer: targeted drug enters final testing
Disease control Not yet recruitingThis study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Alzheimer's in down syndrome: drug trial launches
Disease control Not yet recruitingThe purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an o…
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to shrink sinus tumors before surgery
Disease control Not yet recruitingThe main objective of this prospective study is to evaluate the effectiveness and safety of a novel neoadjuvant therapy for patients with locally advanced sinonasal carcinoma (SNC). The treatment consists of the standard TP chemotherapy regimen (docetaxel and cisplatin) combined …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a simple pill shield HAE patients from Procedure-Triggered attacks?
Disease control Not yet recruitingThis is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
Phase: PHASE4 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a new biologic drug prevent COPD Flare-Ups?
Disease control Not yet recruitingThe purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a custom mRNA vaccine keep ovarian cancer from coming back?
Disease control Not yet recruitingThis is a Phase I, single-arm, open-label, prospective, non-randomized, single-center dose-escalation study. The study will evaluate the safety, tolerability, and preliminary activity of the NeoOVSV mRNA-lipid nanoparticle vaccine in patients with stage II/III ovarian cancer afte…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New study aims to slash cervical cancer deaths in HIV-positive women
Knowledge-focused Not yet recruitingBackground In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC). Women living with HIV (WLWH) have a six-fold higher risk of developing precancerous lesi…
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control Not yet recruitingThis is a phase 2 multicenter study that will evaluate the safety and efficacy of sacituzumab tirumotecan (Sac-TMT) plus fruquintinib for the treatment of participants with locally advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma who have faile…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Brain bleed breakthrough? Two-Drug combo aims to stabilize blood pressure and save lives
Disease control Not yet recruitingIntracerebral hemorrhage (ICH) remains the most devastating subtype of stroke, with a case fatality rate of approximately 40% at one months post-onset, imposing a particularly heavy medical and economic burden on low- and middle-income countries. Studies have shown that poor prog…
Phase: NA • Sponsor: The Third Affiliated Hospital of Southern Medical University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Magnetic heat zaps infection in knee implants without removal
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection. The main questions this study aims to answer are:…
Phase: NA • Sponsor: Solenic Medical, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Overdose prevention program aims to save homeless Veterans' lives
Disease control Not yet recruitingHomeless Overdose Prevention - Expansion (HOPE), tests implementation of overdose education and naloxone distribution (OEND), a program that targets homeless experienced Veterans at risk for overdose, including Veterans in community-based supportive housing. HOPE sites will recei…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a new biologic drug delay dangerous lung Flare-Ups?
Disease control Not yet recruitingThe purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo aims to shrink skin cancer before surgery
Disease control Not yet recruitingThe NEOPECS trial is a phase II prospective, single-arm, non-randomised interventional trial for patients with borderline resectable locally advanced cutaneous squamous cell carcinoma with a 6-participant safety lead in to ensure safety of the combination in the neoadjuvant setti…
Phase: PHASE2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
AI chat could be a secret weapon against dementia in lonely seniors
Disease control Not yet recruitingThis randomized controlled trial examines the mechanisms of conversational AI-based interventions for early dementia prevention in socially isolated older adults.
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC